Omid Omidvar

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

Joseph Jankovic, Ira Goodman, Beth Safirstein et al. · JAMA Neurology · 2018 · 283 citations · Full text

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Danna Jennings, Sarah Huntwork‐Rodriguez, Anastasia G. Henry et al. · Science Translational Medicine · 2022 · 230 citations

Amyloid-β ¹¹ C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Enchi Liu, Mark E. Schmidt, Richard Margolin et al. · Neurology · 2015 · 149 citations · Full text

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Daniel K. Burns, Robert Alexander, Kathleen A. Welsh‐Bohmer et al. · The Lancet Neurology · 2021 · 108 citations

Neurodegenerative Diseases, Neuropsychology, Alzheimer's Disease +11

Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia

Theresa A. Zesiewicz, Frederic Heerinckx, Robert De Jager et al. · Movement Disorders · 2018 · 83 citations